{
    "clinical_study": {
        "@rank": "51790", 
        "arm_group": [
            {
                "arm_group_label": "BI 655075 single rising doses 1", 
                "arm_group_type": "Experimental", 
                "description": "1 h infusion"
            }, 
            {
                "arm_group_label": "BI 655075 single rising doses 2", 
                "arm_group_type": "Experimental", 
                "description": "5 min infusion"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "arm_group_type": "Experimental", 
                "description": "short infusion with 2 capsules dabigatran"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI\n      655075 following intravenous administration of single rising doses of BI 655075 when\n      administered alone and after administration of dabigatran."
        }, 
        "brief_title": "Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "145", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688830", 
            "org_study_id": "1321.1", 
            "secondary_id": "2012-003611-66"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "short infusion", 
                "intervention_name": "BI 655075", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single rising doses 1", 
                "description": "1h infusion", 
                "intervention_name": "BI 655075", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single rising doses 2", 
                "description": "placebo", 
                "intervention_name": "Placebo to dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "2 capsules dabigatran", 
                "intervention_name": "dabigatran", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single rising doses 2", 
                "description": "5 min infusion", 
                "intervention_name": "BI 655075", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 single rising doses 1", 
                "description": "placebo", 
                "intervention_name": "Placebo to dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 655075 with dabigatran", 
                "description": "BI 655075 to placebo", 
                "intervention_name": "Placebo to BI 655075", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium"
                }, 
                "name": "1321.1.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers. to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal and Health Products"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability of BI 655075 (part 1) and BI 655075 administered with dabigatran (part 2) will be assessed based on the number (%) of subjects with adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688830"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 14 weeks"
            }, 
            {
                "measure": "tmax (time from dosing to maximum measured concentration)", 
                "safety_issue": "No", 
                "time_frame": "up to 14 weeks"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 14 weeks"
            }, 
            {
                "measure": "Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)", 
                "safety_issue": "No", 
                "time_frame": "up to 14 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}